C12N 2760/20211
Vesiculovirus
Official title: Vesiculovirus, e.g. vesicular stomatitis Indiana virus
C12N2760/20211 (Vesiculovirus) appears on 309 US grants and 548 published applications in this corpus.
Search patents in C12N- Granted patents
- 309
- Published applications
- 548
- Assignees
- 266
- Inventors
- 994
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 2 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 3 | 0 |
| 1998 | 6 | 0 |
| 1999 | 4 | 0 |
| 2000 | 6 | 0 |
| 2001 | 10 | 3 |
| 2002 | 11 | 5 |
| 2003 | 8 | 18 |
| 2004 | 4 | 8 |
| 2005 | 2 | 8 |
| 2006 | 7 | 6 |
| 2007 | 4 | 14 |
| 2008 | 2 | 6 |
| 2009 | 6 | 14 |
| 2010 | 4 | 19 |
| 2011 | 9 | 17 |
| 2012 | 11 | 18 |
| 2013 | 5 | 13 |
| 2014 | 9 | 20 |
| 2015 | 7 | 15 |
| 2016 | 11 | 13 |
| 2017 | 18 | 25 |
| 2018 | 17 | 15 |
| 2019 | 16 | 25 |
| 2020 | 21 | 25 |
| 2021 | 11 | 32 |
| 2022 | 9 | 27 |
| 2023 | 17 | 38 |
| 2024 | 11 | 73 |
| 2025 | 33 | 50 |
| 2026 | 11 | 41 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/20222New viral proteins or individual genes, new structural or functional aspects ofIndexing code154
- C12N 2760/20241Use of virus, viral particle or viral elements as a vectorIndexing code114
- C12N 2760/20234Use of virus or viral component as vaccineIndexing code67
- C12N 2760/20232Use of virus as therapeutic agent, other than vaccineIndexing code64
- C12N 2760/20261Methods of inactivation or attenuationIndexing code56
- C12N 2760/20251Methods of production or purification of viral materialIndexing code26
- C12N 2760/20221Viruses as suchIndexing code23
- C12N 2760/20223Virus like particles [vlp]Indexing code13
Recent patents
- Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors15 Sep 2026US 12,734,202 B2Joint Biosciences (Sh) Ltd.
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Methods and materials for treating cancer4 Aug 2026US 12,697,361 B2Mayo Foundation for Medical Education and Research
- VSV rescue7 Jul 2026US 12,674,143 B2Boehringer Ingelheim International GmbH
- Unified platform for rapid production of nanovaccines with enhanced safety, efficacy and precision9 Jun 2026US 12,651,648 B2Santa Clara University
- Purification of viruses and viral like particles8 Oct 2026US 2026/0308616 A1Interius Biotherapeutics, Inc.
- Cell surface engineered of tailored therapeutic gene delivery8 Oct 2026US 2026/0308617 A1The Children’s Hospital of Philadelphia
- Modular re-targeting of rhabdoviral (g) glycoproteins from their natural receptors24 Sep 2026US 2026/0285912 A1Vyriad, Inc.
- Vector production24 Sep 2026US 2026/0286391 A1Fondazione Telethon Ets
- Pseudotyped retroviral vector particle with anti-cd3 display24 Sep 2026US 2026/0286392 A1Miltenyi Biotec GmbH
Most cited
By later US patents
- Vector and method of use for nucleic acid delivery to non-dividing cells323US 6,013,516 AThe Salk Institute for Biological Studies · 2000
- Composition and methods for transfecting eukaryotic cells122US 5,578,475 ALife Technologies Corporation · 1996
- Stranded RNA virus particles108US 5,789,229 AThe UAB Research Foundation · 1998
- Viruses with recombinant surface proteins96US 4,593,002 AThe Salk Institute Biotechnology/Industrial Associates, Inc. · 1986
- Photodynamic inactivation of viruses in blood cell-containing compositions94US 5,120,649 ANew York Blood Center, Inc. · 1992